BioNano Genomics Inc (NASDAQ: BNGO) Is Included In Small-Cap Russell 2000® Index, Ashford Hospitality Trust, Inc. (NYSE: AHT) Preparing To Be Included In The Russell 2000®, Russell 3000® And Russell Microcap® Indexes

June 30, 2021

BioNano Genomics Inc (NASDAQ: BNGO) has made it official that it has found a place in the U.S. small-cap Russell 2000® Index. Companies that make it to the list are eligible to be members for one year. BioNano Genomics Inc is a genome analysis company that supports scientists with the tools in clinicians conducting genetic research, patient testing, and diagnostic testing for patients diagnosed with Autism Spectrum Disorder (ASD) and…

Read More >>

While Lineage Cell Therapeutics Inc (NYSEAMERICAN: LCTX) In Russell 3000® and Russell Microcap® Indexes, Inpixon (NASDAQ: INPX) Included In The Russell Microcap® Index

June 30, 2021

Lineage Cell Therapeutics Inc (NYSEAMERICAN: LCTX), a clinical-stage biotechnology company involved in developing allogeneic cell therapies for unmet medical needs, in an official statement, announced that the company had made it to broad-market Russell 3000® Index as well as the Russell Microcap® Index. Inpixon (NASDAQ: INPX) included in Russell Microcap® Index Inpixon (NASDAQ: INPX), the Indoor Intelligence™ company, announced that it had made it to the Russell Microcap® Index. By…

Read More >>

IJP Corporation (OTCMKTS:IJJP) stock Is Down 20%: What’s Going On?

June 29, 2021

In the past week, the IJP Corporation (OTCMKTS:IJJP) stock has suffered from a pretty strong selloff and declined by as much as 20% during the period. In this regard, it might be a good time for investors to start looking into some of the recent development with regards to the company. Yesterday, the company noted that its Pink Current Information status is still in the final stage of review with…

Read More >>

Caladrius Biosciences Inc. (NASDAQ: CLBS) Jumps 4.5% After FDA Approves Its CLBS201 IND in Diabetic Kidney Disease

June 29, 2021

Caladrius Biosciences Inc. (NASDAQ: CLBS) climbed 4.46% after the FDA approved its Investigational New Drug Application for the CLBS201 study. CLBS201 is a CD34+ cell therapy for diabetic kidney disease treatment.  Caladrius evaluating CLBS20’s efficacy and safety  David J. Mazzo, the company’s CEO and President said, “Our latest development program, CLBS201, is designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for diabetic patients with…

Read More >>

Antares Pharma Inc. (NASDAQ: ATRS) Submits IND for ATRS-1902 Clinical Study In Adrenal Crisis Management

June 29, 2021

Antares Pharma Inc. (NASDAQ: ATRS) has announced an Investigational New Drug Application to the FDA to commence its Phase 1 ATRS-1902 clinical study to treat adrenal crisis rescue.  Adrenal crisis is associated with cortisol deficiency  The ATRS-1902 application and corresponding development program support proposed acute adrenal insufficiency (adrenal crisis) treatment using a new proprietary auto-injector delivery platform for hydrocortisone.  Dr. Peter Richardson, Antares Pharma EVP R&D, and Chief Medical Officer…

Read More >>

Lineage Cell Therapeutics Inc. (NYSEAMERICAN: LCTX) Gains After FDA Gives Feedback On OPC1 IND

June 29, 2021

Lineage Cell Therapeutics Inc. (NYSEAMERICAN: LCTX) gained 2.16% after releasing an update in OPC1’s clinical development. OPC1 is the company’s experimental allogeneic oligodendrocyte progenitor cell (OPC) transplant therapy for spinal cord injury treatment.  Lineage receives FDA feedback on OPC1 IND Last week the company received feedback from the FDA under the US FDA’s Regenerative Medicine Advanced Therapy program. As a result, Lineage is planning to submit an amendment to its…

Read More >>

Lineage Cell Therapeutics Inc (NYSEAMERICAN: LCTX) Brings Onboard Kevin Cook To Serve As The Company’s Chief Financial Officer

June 25, 2021

Lineage Cell Therapeutics Inc (NYSEAMERICAN: LCTX) is quite pleased to make Kevin Cook its new Chief Financial Officer, effective June 21, 2021. It believes that the official will greatly contribute to its efforts to grow and become a top cell therapy and cell Transplant Company. The company considered Cook’s qualifications and track record The company chose Cook after considering the value he would bring to its business. That starts with his…

Read More >>

PharmaCyte Biotech (OTCMKTS:PMCB) Stock Extends Rally: Up 55% in a Week

June 24, 2021

In recent times, the PharmaCyte Biotech Inc (OTCMKTS:PMCB) stock has emerged as a notable gainer in the biotech space and the strong move has continued this morning. This morning the stock has carried on its momentum and soared by 13% to takes its gains for the past week to as much as 55%. Earlier today, the stock has come on to the radars of investors after it announced the steps…

Read More >>

Allied Energy Corp (OTCMKTS:AGYP) Rework Activities Starts at Two Lease Sites

June 22, 2021

Energy company Allied Energy Corp (OTCMKTS:AGYP) recently made an important announcement regarding their rework activities to two of their leasing sites. The energy company has scheduled workers to its Green Lease site and its Annie Gilmer site, according to the CEO of Allied Energy Corp George Montieth. The Green Lease site has cleared its wellsite location and built base pads for the brand new pumping units, as well as repairs…

Read More >>

Why Helium Play Avanti Energy, Inc. (OTCMKTS:ARGYF) (CVE:AVN) is Blowing Up.

Why Helium Play Avanti Energy, Inc. (OTCMKTS:ARGYF) (CVE:AVN) is Blowing Up.
June 15, 2021

Avanti Energy, Inc. (OTCMKTS:ARGYF) (CVE:AVN) a helium exploration, development and production company operating in western Canada and the United States, just announced agreements to acquire two properties totalling ~50,000 acres of land in Montana. These potential acquisitions would add to ARGYF’s portfolio of projects including the Knappen and Aden projects both located in Alberta, Canada.

Read More >>